{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:35:22Z","timestamp":1791279322962,"version":"4.1.0"},"reference-count":90,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002047","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:33:39Z","timestamp":1069367619000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Leflunomide for the treatment of rheumatoid arthritis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Manathip","family":"Osiri","sequence":"first","affiliation":[{"name":"Faculty of Medicine; Department of Medicine; Chulalongkorn University 1873 Rama IV Road, Pathumwan Bangkok Thailand 10330"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[{"name":"University of Ottawa; Institute of Population Health; 1 Stewart St. Room 312 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Welch","sequence":"additional","affiliation":[{"name":"University of Ottawa; Centre for Global Health, Institute of Population Health; 1 Stewart Street, Room 206 Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"The University of Texas, M.D. Anderson Cancer Center; General Internal Medicine, Ambulatory Treatment and Emergency Care; 1515 Holcombe Blvd Unit 1465 Houston Texas USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Stanford University; Division of Immunology; 306 Ramona Road Portola Valley California USA 94028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Ottawa Hospital; Centre for Global Health, Institute of Population Health, Department of Medicine; 1 Stewart Street Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute; Cardiovascular Research Reference Centre; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,7,22]]},"reference":[{"key":"10.1002\/14651858.CD002047-BIB0001|cit1","unstructured":"Amit M A comparative 2-year clinical study of combined leflunomide and methotrexate vs methotrexate alone as DMARD in rheumatoid arthritis Abstract book, the 11th APLAR meeting, Jeju, South Korea Seoul Sep 2004 93"},{"key":"10.1002\/14651858.CD002047-BIB0002|cit2","first-page":"A190","article-title":"A comparative 3-year clinical study of combined leflunomide and methotrexate vs methotrexate alone as DMARD in rheumatoid arthritis","volume":"9 Suppl 1","author":"Amit","year":"2006","journal-title":"The Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD002047-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4103\/0019-5359.26608","article-title":"Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis","volume":"60","author":"Antony","year":"2006","journal-title":"Indian Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD002047-BIB0004|cit4","first-page":"44","article-title":"Treatment of rheumatoid arthritis with leflunomide: a double blind, randomised controlled study","volume":"4","author":"Bao","year":"2000","journal-title":"China Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD002047-BIB0005|cit5","first-page":"1228","article-title":"Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial","volume":"116","author":"Bao","year":"2003","journal-title":"Chinese Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD002047-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD002047-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ard.2003.016709","article-title":"When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?","volume":"64","author":"Dougados","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD002047-BIB0008|cit8","first-page":"271","article-title":"Efficacy and safety of leflunomide vs. methotrexate in rheumatoid arthritis (RA): results of a double-blind, randomized, 2-year trial","volume":"42 Suppl","author":"Emery","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD002047-BIB0010|cit10","unstructured":"Emery P Breedveld FC Lemmel EM A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis Data on file, Hoechst Marion Roussel (Bridgewater)"},{"key":"10.1002\/14651858.CD002047-BIB0011|cit11","first-page":"2","article-title":"Summary basis of approval, leflunomide: NDA 20-905","volume-title":"Summary basis of approval, United States Department of Health and Human Services","volume":"ND 20-905","author":"United States","year":"1997"},{"issue":"10","key":"10.1002\/14651858.CD002047-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00296-007-0347-0","article-title":"Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone","volume":"27","author":"Fiehn","year":"2007","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD002047-BIB0013|cit13","unstructured":"Gao JS Wu H Chen YJ Li F Tian J Xie X Observation on the short-term curative effect and safety on combination use of LEF plus MTX in the treatment of active and severe RA Abstract book, the 11th APLAR meeting, Jeju, South Korea Seoul Sep 2004 92"},{"issue":"1","key":"10.1002\/14651858.CD002047-BIB0014|cit14","first-page":"72","article-title":"A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis","volume":"21","author":"Hu","year":"2001","journal-title":"Journal of Tongji Medical University"},{"key":"10.1002\/14651858.CD002047-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1297-319X(02)00397-4","article-title":"Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study","volume":"69","author":"Jakez-Ocampo","year":"2002","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"issue":"2","key":"10.1002\/14651858.CD002047-BIB0016|cit16","first-page":"157","article-title":"Efficacy in Active Rheumatoid Arthritis Treated by Leflunomide in Comparison with Methotrexate: A Randomized and Controlled Trial","volume":"8","author":"Jiang","year":"2001","journal-title":"Clinical Medical Journal of China"},{"issue":"9","key":"10.1002\/14651858.CD002047-BIB0017|cit17","first-page":"1983","article-title":"Improved functional ability in patients with rheumatoid arthritis - long term treatment with leflunomide versus sulfasalazine","volume":"28","author":"Kalden","year":"2001","journal-title":"The Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD002047-BIB0018|cit18","first-page":"486","article-title":"Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis","volume":"33","author":"Karanikolas","year":"2006","journal-title":"The Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD002047-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","article-title":"Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Kremer","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002047-BIB0020|cit20","first-page":"1521","article-title":"Combination leflunomide and methotrexate therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial","volume":"31","author":"Kremer","year":"2004","journal-title":"The Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD002047-BIB0021|cit21","first-page":"94","article-title":"Leflunomide in treating rheumatoid arthritis: a double-blind study","volume":"20","author":"Lao","year":"2001","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"10.1002\/14651858.CD002047-BIB0022|cit22","unstructured":"Lao ZY Chen JH Leflunomide combined with MTX in the treatment of rheumatoid arthritis Abstract book, the 10th APLAR congress, Bangkok, Thailand Bangkok Dec 2002 140"},{"issue":"3","key":"10.1002\/14651858.CD002047-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/030097401300162897","article-title":"Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine","volume":"30","author":"Larsen","year":"2001","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002047-BIB0024|cit24","unstructured":"Lau CS on behalf of the ARAVA Asia Study Group Leflunomide (LEF) versus low dose methotrexate (MTX) in adult Asian patients with active rheumatoid arthritis (RA) Abstract book, the 10th APLAR congress, Bangkok, Thailand Bangkok Dec 2002 141"},{"key":"10.1002\/14651858.CD002047-BIB0025|cit25","first-page":"278","article-title":"Efficacy evaluation of adalimumab (Humira\u00ae) in combination with single and multiple disease modifying antirheumatic drugs in the REACT trial","volume":"63 Suppl 1","author":"Mariette","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD002047-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.1780381111","article-title":"Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis","volume":"38","author":"Mladenovic","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/rheumatology\/keh168","article-title":"Efficacy and safety of leflunomide 10 mg vs 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial","volume":"43","author":"Strand","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1002\/14651858.CD002047-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/art.10084","article-title":"Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging","volume":"46","author":"Reece","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD002047-BIB0029|cit29","first-page":"339","article-title":"Weekly administration of leflunomide to patients with active rheumatoid arthritis","volume":"37 Suppl 9","author":"Rozman","year":"1994","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD002047-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.60.10.913","article-title":"Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine","volume":"60","author":"Scott","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002047-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD002047-BIB0032|cit32","first-page":"41","article-title":"The phase II clinical trial of leflunomide in treatment of rheumatoid arthritis","volume":"37","author":"Shuai","year":"2002","journal-title":"Acta Universitatis Medicinalis Anhui"},{"key":"10.1002\/14651858.CD002047-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002047-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate","volume":"159","author":"Strand","year":"1999","journal-title":"Archives in Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD002047-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/1529-0131(199909)42:9<1870::AID-ANR11>3.0.CO;2-D","article-title":"Function and health-related quality of life: results form a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis","volume":"42","author":"Strand","year":"1999","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD002047-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00296-006-0272-7","article-title":"Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-\u03b1 blocker plus methotrexate versus methotrexate or leflunomide alone","volume":"27","author":"Wislowska","year":"2007","journal-title":"Rheumatology International"},{"issue":"5","key":"10.1002\/14651858.CD002047-BIB0037|cit37","first-page":"28","article-title":"Changes in indices of inflammatory activity in patients with rheumatoid arthritis during early stages of basic therapy with leflunomide","volume":"76","author":"Balabanova","year":"2004","journal-title":"Terapevticheskii Arkhiv"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0038|cit38","first-page":"6","article-title":"An antidestructive effect of leflunomide in early rheumatoid arthritis","volume":"78","author":"Balabanova","year":"2006","journal-title":"Terapevticheskii Arkhiv"},{"issue":"12","key":"10.1002\/14651858.CD002047-BIB0039|cit39","first-page":"2572","article-title":"Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data","volume":"30","author":"Dougados","year":"2003","journal-title":"The Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD002047-BIB0040|cit40","first-page":"328","article-title":"Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis","volume":"22","author":"Godinho","year":"2004","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD002047-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MLR.0b013e318041384c","article-title":"Assessment of adherence to and persistence on disease- modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis","volume":"45 Suppl 2","author":"Grijalva","year":"2007","journal-title":"Medical Care"},{"issue":"2","key":"10.1002\/14651858.CD002047-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/art.20228","article-title":"The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis","volume":"51","author":"Hansen","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD002047-BIB0043|cit43","first-page":"151","article-title":"Contrast enhanced Gd-DTPA magnetic resonance imaging in the evaluation of rheumatoid arthritis during a clinical trial with DMARDs. A prospective two-year follow-up study on hand joints in 31 patients","volume":"15","author":"Jevtic","year":"1997","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/art.22666","article-title":"Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis","volume":"56","author":"Ju","year":"2007 Jun","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/art.11015","article-title":"The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study","volume":"48","author":"Kalden","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD002047-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2003.014738","article-title":"Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis","volume":"63","author":"Kraan","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD002047-BIB0047|cit47","first-page":"43","article-title":"Leflunomide in the treatment of refractory rheumatoid arthritis","volume":"45","author":"Kuzmanova","year":"2003","journal-title":"Folia Medica (Plovdiv)"},{"issue":"2","key":"10.1002\/14651858.CD002047-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2005.12.009","article-title":"The effect of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1, and MMP-3 in patients with resistant rheumatoid arthritis","volume":"33","author":"Litinsky","year":"2006","journal-title":"Cytokine"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0049|cit49","first-page":"66","article-title":"Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis","volume":"17 Suppl 18","author":"Mroczkowski","year":"1999","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD002047-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/S0041-1345(98)01370-0","article-title":"Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporin, and levamisole) in patients with rheumatoid arthritis","volume":"30","author":"Popovic","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD002047-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1445-5994.2007.01266.x","article-title":"Effect of leflunomide on the peripheral nerves in rheumatoid arthritis","volume":"37","author":"Richards","year":"2007","journal-title":"Internal Medicine Journal"},{"issue":"9","key":"10.1002\/14651858.CD002047-BIB0052|cit52","first-page":"339","article-title":"Long term administration of leflunomide to patients with rheumatoid arthritis (RA)","volume":"37 Suppl","author":"Rozman","year":"1994","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD002047-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/rheumatology\/kem278","article-title":"The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis","volume":"46","author":"Saruhan-Direskeneli","year":"2007","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD002047-BIB0054|cit54","first-page":"590","article-title":"Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis","volume":"32","author":"Strand","year":"2005","journal-title":"The Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD002047-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.2006.067827","article-title":"Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients","volume":"67","author":"Tchetverikov","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/ard.2003.010983","article-title":"Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years","volume":"63","author":"Heijde","year":"2004 Jun","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD002047-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/ard.2006.066662","article-title":"Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score","volume":"66","author":"Kooij","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0058|cit58","first-page":"695","article-title":"Lelfunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate","volume":"21","author":"Riel","year":"2003","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD002047-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/ard.2004.025205","article-title":"Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis","volume":"64","author":"Roon","year":"2005 Apr","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD002047-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P","article-title":"Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis","volume":"42","author":"Weinblatt","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"132","key":"10.1002\/14651858.CD002047-BIB0061|cit61","first-page":"547","article-title":"Leflunomide as a second choice treatment in patients with rheumatoid arthritis","volume":"22","author":"Raczkiewicz-Papierska","year":"2007","journal-title":"Polski Merkuriusz Lekarski"},{"issue":"3-4","key":"10.1002\/14651858.CD002047-BIB0062|cit62","first-page":"34","article-title":"Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis","author":"Shevchuk","year":"2003","journal-title":"Likarska Sprava"},{"issue":"12","key":"10.1002\/14651858.CD002047-BIB0063|cit63","first-page":"1038","article-title":"Methotrexate combined with leflunomide or hydroxychloroquine in the treatment of rheumatoid arthritis","volume":"84","author":"Zhang","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"4","key":"10.1002\/14651858.CD002047-BIB0064|cit64","first-page":"355","article-title":"Clinical observation on effects of leflunomide and total glucosides of paeony on rheumatoid arthritis","volume":"26","author":"Zhao","year":"2006","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"key":"10.1002\/14651858.CD002047-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0889-857X(21)00458-0","article-title":"Epidemiology of rheumatoid arthritis","volume":"21","author":"Alarcon","year":"1995","journal-title":"Rheumatic Diseases Clinics of North America"},{"key":"10.1002\/14651858.CD002047-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD002047-BIB0067|cit67","first-page":"2208","article-title":"Patients with rheumatoid arthritis benefit from early second line therapy: 5-year follow up of a prospective, double blind, placebo controlled study","volume":"22","author":"Egsmose","year":"1995","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002047-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD002047-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis & Rheumatism"},{"issue":"53","key":"10.1002\/14651858.CD002047-BIB0070|cit70","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis","volume":"25 Suppl","author":"Fox","year":"1998","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002047-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.1780390412","article-title":"Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies","volume":"39","author":"Fries","year":"1996","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD002047-BIB0072|cit72","first-page":"14","article-title":"Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors","volume":"38 Suppl 2","author":"Furst","year":"1999","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD002047-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jamia.1994.95153434","article-title":"Developing optimal search strategies for detecting clinically sound studies in MEDLINE","volume":"1","author":"Haynes","year":"1994","journal-title":"Journal of the American Medical Informatics Association"},{"key":"10.1002\/14651858.CD002047-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD002047-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of randomized trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/art.10793","article-title":"Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"47","author":"Maetzel","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD002047-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G","article-title":"ACR20: clinical or statistical significance?","volume":"42","author":"Pincus","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"53","key":"10.1002\/14651858.CD002047-BIB0078|cit78","first-page":"27","article-title":"Clinical experience with leflunomide in rheumatoid arthritis","volume":"25 Suppl","author":"Rozman B for the Leflunomide Investigators Group","year":"1998","journal-title":"The Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD002047-BIB0080|cit80","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Sch\u00fcnemann","year":"Updated Sep 2008"},{"key":"10.1002\/14651858.CD002047-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/oxfordjournals.rheumatology.a031493","article-title":"New and future drug therapies for rheumatoid arthritis","volume":"39 Suppl 1","author":"Simon","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD002047-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/oxfordjournals.rheumatology.a031495","article-title":"Efficacy and safety of leflunomide in active rheumatoid arthritis","volume":"39 Suppl 1","author":"Smolen","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD002047-BIB0083|cit83","volume-title":"Evidence-based Rheumatology","author":"Tugwell","year":"2004"},{"key":"10.1002\/14651858.CD002047-BIB0084|cit84","first-page":"573","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"Heijde","year":"1993","journal-title":"The Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002047-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism criteria","volume":"39","author":"Gestel","year":"1996","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD002047-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: a criteria list for quality assessment of randomized controlled trials for conducting systematic review developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD002047-BIB0087|cit87","first-page":"19","article-title":"The role of current strategies in the future treatment of rheumatoid arthritis","volume":"38 Suppl 2","author":"Weinblatt","year":"1999","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD002047-BIB0088|cit88","first-page":"1290","article-title":"Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis","volume":"18","author":"Wolfe","year":"1991","journal-title":"The Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD002047-BIB0089|cit89","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"30","author":"Osiri","year":"2003","journal-title":"The Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD002047-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002047","article-title":"Leflunomide for the treatment of rheumatoid arthritis","author":"Osiri","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002047\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:04:38Z","timestamp":1783904678000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002047"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2002,7,22]]},"references-count":90,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002047","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,22]]}}}